Skye Bioscience, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

SKYE$0.84+21.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations for the (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Three Months EndedJune 30,		For the Six Months EndedJune 30,
	2026	2025	2026	2025
Operating expenses
Research and development	$3,941,932	$14,337,753	$11,877,612	$21,535,010
General and administrative	3,869,371	3,906,172	8,608,057	8,468,477
Change in estimate for legal contingency	3,250,000	—	3,250,000	—
Total operating expenses	11,061,303	18,243,925	23,735,669	30,003,487
Operating loss	(11,061,303)	(18,243,925)	(23,735,669)	(30,003,487)
Other (income) expense
Interest expense	3,299	—	5,498	—
Interest and other income, net	(103,208)	(533,090)	(272,823)	(1,191,333)
Gains from asset sales	(178,200)	(89,363)	(178,200)	(89,363)
Other expense	—	—	2,411	—
Total other (income) expense, net	(278,109)	(622,453)	(443,114)	(1,280,696)
Loss before income taxes	(10,783,194)	(17,621,472)	(23,292,555)	(28,722,791)
Provision for income taxes	3,400	3,400	3,400	5,400
Net loss	$(10,786,594)	$(17,624,872)	$(23,295,955)	$(28,728,191)
Loss per common share:
Basic	$(0.27)	$(0.44)	$(0.59)	$(0.72)
Diluted	$(0.27)	$(0.44)	$(0.59)	$(0.72)
Weighted average shares of common stock outstanding used to compute loss per share:
Basic	39,694,243	39,659,266	39,687,418	39,655,597
Diluted	39,694,243	39,659,266	39,687,418	39,655,597

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.